Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.

Autor: Thompson MA; Aurora Cancer Care, Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI,. Electronic address: michael.thompson@tempus.com., Boccadoro M; Division of Hematology, University of Torino, Torino, Italy., Leleu X; Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, France., Vela-Ojeda J; Department of Hematology, UMAE Hospital de Especialidades Centro Medico La Raza IMSS, Mexico City, Mexico., van Rhee F; University of Arkansas for Medical Sciences, Little Rock, AR., Weisel KC; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Rifkin RM; Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO., Usmani SZ; Levine Cancer Institute, Charlotte, NC., Hájek R; Department of Hemato-oncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Cook G; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK., Abonour R; Indiana University School of Medicine, Indianapolis, IN., Armour M; Mijelom CRO, Croatian Myeloma Support Association, Zagreb, Croatia., Morgan KE; Myeloma Patients Europe, Brussels, Belgium., Yeh SP; China Medical University Hospital, Taichung City, P.R.China., Costello CL; University of California San Diego, La Jolla, CA., Berdeja JG; Department of Hematology, Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN., Davies FE; Perlmutter Cancer Center, NYU Langone, New York, NY., Zonder JA; Department of Malignant Hematology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI., Lee HC; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX., Omel J; The Central Nebraska Myeloma Support Group, Grand Island, NE., Spencer A; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health Monash University, Melbourne, Australia., Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Hungria VTM; Department of Hematology, Clinica São Germano and Santa Casa Medical School, São Paulo, Brazil., Puig N; Hematology Department, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain., Fu C; First Affiliated Hospital, Soochow University, Suzhou Jiangsu, P.R.China., Ferrari RH; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA., Ren K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA., Stull DM; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA., Chari A; Department of Hematology-Oncology, Mount Sinai School of Medicine, New York, NY.
Jazyk: angličtina
Zdroj: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Mar; Vol. 23 (3), pp. e171-e181. Date of Electronic Publication: 2022 Dec 07.
DOI: 10.1016/j.clml.2022.12.003
Abstrakt: Background: Infections are a common reason for hospitalization and death in multiple myeloma (MM). Although pneumococcal vaccination (PV) and influenza vaccination (FV) are recommended for MM patients, data on vaccination status and outcomes are limited in MM.
Materials and Methods: We utilized data from the global, prospective, observational INSIGHT MM study to analyze FV and PV rates and associated outcomes of patients with MM enrolled 2016-2019.
Results: Of the 4307 patients enrolled, 2543 and 2500 had study-entry data on FV and PV status. Overall vaccination rates were low (FV 39.6%, PV 30.2%) and varied by region. On separate multivariable analyses of overall survival (OS) by Cox model, FV in the prior 2 years and PV in the prior 5 years impacted OS (vs. no vaccination; FV: HR, 0.73; 95% CI, 0.60-0.90; P = .003; PV: HR, 0.51; 95% CI, 0.42-0.63; P < .0001) when adjusted for age, region, performance status, disease stage, cytogenetics at diagnosis, MM symptoms, disease status, time since diagnosis, and prior transplant. Proportions of deaths due to infections were lower among vaccinated versus non-vaccinated patients (FV: 9.8% vs. 15.3%, P = .142; PV: 9.9% vs. 18.0%, P = .032). Patients with FV had generally lower health resource utilization (HRU) versus patients without FV; patients with PV had higher or similar HRU versus patients without PV.
Conclusion: Vaccination is important in MM and should be encouraged. Vaccination status should be recorded in prospective clinical trials as it may affect survival. This trial was registered at www.
Clinicaltrials: gov as #NCT02761187.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: